News Room

Latest Announcements

Huntington's Disease

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

Prana Biotechnology today announced that the first patient has been dosed in the “Reach2HD Trial” – a 6 month Phase IIa clinical trial testing PBT2, the Company’s drug in development for Huntington disease. Reach2HD, a double blind placebo controlled study, is enrolling 100 patients with early to mid-stage Huntington Disease. The Principal Investigator on the study is Dr. Ray Dorsey of Johns Hopkins University.

Alzheimer’s Disease

PLoS ONE Journal Publishes Mechanistic Model of Alzheimer’s Disease Endorsing Prana’s PBT2

Prana Biotechnology today announced the publication in the journal PLoS ONE, of an article that strongly endorses PBT2’s potential to treat Alzheimer’s Disease. The paper, entitled “The Zinc Dyshomeostasis Hypothesis of Alzheimer’s Disease”1 presents an integrated explanation of the major pathological features of Alzheimer’s Disease, based upon a combination of new experimental data and mathematical modeling.

Investor Announcement

Professor Rudy Tanzi Appointed Prana’s Chief Scientific Advisor

Professor Rudy Tanzi has been appointed as Chief Scientific Advisor to the Company. Professor Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). Professor Tanzi has been investigating the genetics of neurological disease since 1980 when he participated in the study that led to the first disease gene being identified by genetic analysis (Huntington’s Disease).

1 7 8 9